Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience

Sawas Ahmed; Ma Helen; Kuruvilla John; Lue Jennifer K.; Deng Changchun; Marchi Enrica; Montanari Francesca; Cheng Bin; Savage Kerry J.; Villa Diego; Crump Michael; Connors Joseph M.; OConnor Owen A.

首页> 外文期刊>Leukemia and lymphoma >Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience

【24h】

Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience

机译：在重复或难治性Hodgkin淋巴瘤的严重治疗患者中，响应者的组合的响应者组合的延长进展免疫生存在巨大治疗的霍奇金淋巴瘤中：国际多中心阶段I / II经验的更新结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia and lymphoma》 |2020年第12期|共4页
作者
Sawas Ahmed; Ma Helen; Kuruvilla John; Lue Jennifer K.; Deng Changchun; Marchi Enrica; Montanari Francesca; Cheng Bin; Savage Kerry J.; Villa Diego; Crump Michael; Connors Joseph M.; OConnor Owen A.;
展开▼
作者单位

Columbia Univ Ctr Lymphoid Malignancies Irving Med Ctr New York NY USA;

Columbia Univ Ctr Lymphoid Malignancies Irving Med Ctr New York NY USA;

Univ Toronto Princess Margaret Canc Ctr Div Med Oncol &

Hematol Toronto ON Canada;

Columbia Univ Ctr Lymphoid Malignancies Irving Med Ctr New York NY USA;

Columbia Univ Ctr Lymphoid Malignancies Irving Med Ctr New York NY USA;

Columbia Univ Ctr Lymphoid Malignancies Irving Med Ctr New York NY USA;

Columbia Univ Ctr Lymphoid Malignancies Irving Med Ctr New York NY USA;

Columbia Univ Ctr Lymphoid Malignancies Irving Med Ctr New York NY USA;

BC Canc Ctr Lymphoid Canc Vancouver BC Canada;

BC Canc Ctr Lymphoid Canc Vancouver BC Canada;

Univ Toronto Princess Margaret Canc Ctr Div Med Oncol &

Hematol Toronto ON Canada;

BC Canc Ctr Lymphoid Canc Vancouver BC Canada;

Univ Virginia Ctr Canc Div Hematol &

Oncol Charlottesville VA 22903 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin [J] . Zhi-Gang Cao, Hong-Wei Zhou, Chao-Jin Peng, 癌症（英文版） . 2013,第009期
2. Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma:a multicenter,open-label,single-arm,phase 3 study [J] . Yuan-Kai Shi, Jian-Qiu Wu, Ming-Zhi Zhang, 中华医学杂志（英文版） . 2021,第011期
3. Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience [J] . Sawas Ahmed, Kuruvilla John, Lue Jennifer Kimberly, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：响应者延长的整体存活率（OS）在患有压缩或难治性Hodgkin淋巴瘤（HL）的严重治疗患者中的Brentuximab Vedotin（BV）和Bendamustine（B）的组合：国际多中心阶段I / II的结果经验
4. Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing) [J] . Advani Ranjana H., Moskowitz Alison J., Bartlett Nancy L., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：Brentuximab vEdotin的第1/2期与Nivolumab在复发或难治性经典霍奇金淋巴瘤患者中的组合研究：第3部分（并发给药）结果和更新的无进展的存活结果来自第1和第2部分（交错剂量）
5. Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG) [J] . Czyz Anna, Lojko-Dankowska Anna, Joks Monika, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：单独的Brentuximab Vedotin并与Bendamustine组合作为初级耐火或复发的霍格金淋巴瘤的救生疗法：波兰淋巴瘤研究组的多期体验（PLRG）
6. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
7. Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma [O] . Tsung-Ying Yu, Ming-Shen Dai 2020

机译：Pembrolizumab和Brentuximab-Vedotin联合疗法可在长期治疗的复发/难治性霍奇金淋巴瘤中长期缓解
8. High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL) [O] . B. Wannesson, G. Remaggi, D. Intile, 2017

机译：高响应率和Brentuximab Vedotin / Bendamustine组合在重复/难治性Hodgkin淋巴瘤（HL）中的患者中的Brentuximab vedotin / bendamustine组合的安全毒性概况

Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience

著录项

相似文献

相关主题

期刊订阅